Updated Jul 16, 2026
Stazzone Peter has filed 2 SEC Form 4 filings across 1 company in the last 90 days.
Peter Stazzone is the Chief Financial Officer of Lixte Biotechnology Holdings, Inc., a biopharmaceutical company focused on developing Protein Phosphatase 2A inhibitors for cancer treatment. He has been involved in the company's financial operations as indicated by SEC filings.
| Role | Chief Financial Officer |
|---|---|
| Notability | 30/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-07-02 | LIXT | LIXTE BIOTECHNOLOGY HOLDINGS, INC. | A — Grant or award | 50.0K | $0.00 | |
| 2026-04-17 | LIXT | LIXTE BIOTECHNOLOGY HOLDINGS, INC. | A — Grant or award | 50.0K | — |
Peter Stazzone is the Chief Financial Officer of Lixte Biotechnology Holdings, Inc., a biopharmaceutical company focused on developing Protein Phosphatase 2A inhibitors for cancer treatment. He has been involved in the company's financial operations as indicated by SEC filings.…
2 primary Form 4 filings in the last 90 days, covering 1 company.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Stazzone Peter profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.